1. Guest, the two part 'News in Brief' for the week beginning 16th May 2022 is here.
    Dismiss Notice
  2. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Open‐label study with the monoamine stabilizer (‐)‐OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome, Haghighi et al, 2021

Discussion in 'ME/CFS research' started by Andy, Feb 3, 2021.

  1. Andy

    Andy Committee Member

    Hampshire, UK
    Open access, https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.2040
    Lily Valley, Marky, Caesar and 11 others like this.
  2. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Lily Valley, Marky, Caesar and 6 others like this.
  3. leokitten

    leokitten Senior Member (Voting Rights)

    This paper is definitely better than the Abilify retrospective paper, even though it too has limitations being single-arm open label. OSU6162 and Abilify are quite similar drugs and are dopamine and serotonin system stabilizers.

    What do people think about the various endpoints? I don’t feel I have enough experience on the various ratings scales to form an opinion, but they used a number of diverse endpoints.

    In 2017, some of the same group of Swedish researchers as this study conducted a small double-blind RCT of OSU6162


    But that RCT found a null result which I believe was due to a major flaw in their design, they gave the drug (or placebo) for only 2 weeks. Big mistake. Testimonials on Abilify show that it only starts to show results at 2 weeks, and benefits seem to continue to increase for weeks afterward.

    I believe that’s why they did this new study where they gave the drug for 12 weeks and had a higher dosage level (45 mg bid) than the earlier RCT. I really wish they had done this study as a double-blind RCT.
    Anna H, Lily Valley, Marky and 6 others like this.

Share This Page